Moreover, there was no decreased trend in the numbers of CCR7- and CCR7-ICOS+ memory Tfh cells in the MS patients with CR or PR after treatment (Fig 2I, 2J, 2L and 2M). This evidence concerns the gene CCR7 and myeloid sarcoma.